• Title/Summary/Keyword: $^{166}Ho$

Search Result 623, Processing Time 0.028 seconds

Radiation Absorbed Dose Calculation Using Planar Images after Ho-166-CHICO Therapy (Ho-166-CHICO 치료 후 평면 영상을 이용한 방사선 흡수선량의 계산)

  • 조철우;박찬희;원재환;왕희정;김영미;박경배;이병기
    • Progress in Medical Physics
    • /
    • v.9 no.3
    • /
    • pp.155-162
    • /
    • 1998

  • Ho-l66 was produced by neutron reaction in a reactor at the Korea Atomic Energy Institute (Taejon, Korea). Ho-l66 emits a high energy beta particles with a maximum energy of 1.85 MeV and small proportion of gamma rays (80 keV). Therefore, the radiation absorbed dose estimation could be based on the in-vivo quantification of the activity in tumors from the gamma camera images. Approximately 1 mCi of Ho-l66 in solution was mixed into the flood phantom and planar scintigraphic images were acquired with and without patient interposed between the phantom and scintillation camera. Transmission factor over an area of interest was calculated from the ratio of counts in selected regions of the two images described above. A dual-head gamma camera(Multispect2, Siemens, Hoffman Estates, IL, USA) equipped with medium energy collimators was utilized for imaging(80 keV${\pm}$10%). Fifty-nine year old female patient with hepatoma was enrolled into the therapeutic protocol after the informed consent obtained. Thirty millicuries(110MBq) of Ho-166-CHICO was injected into the right hepatic arterial branch supplying hepatoma. When the injection was completed, anterior and posterior scintigraphic views of the chest and pelvic regions were obtained for 3 successive days. Regions of interest (ROIs) were drawn over the organs in both the anterior and posterior views. The activity in those ROIs was estimated from geometric mean, calibration factor and transmission factors. Absorbed dose was calculated using the Marinelli formula and Medical Internal Radiation Dose (MIRD) schema. Tumor dose of the patient treated with 1110 MBq(30 mCi) Ho-l66 was calculated to be 179.7 Gy. Dose distribution to normal liver, spleen, lung and bone was 9.1, 10.3, 3.9, 5.0 % of the tumor dose respectively. In conclusion, tumor dose and absorbed dose to surrounding structures were calculated by daily external imaging after the Ho-l66 therapy for hepatoma. In order to limit the thresholding dose to each surrounding organ, absorbed dose calculation provides useful information.

  • PDF

Development of a Radiopharmaceutical using 166Ho-chitosan Complexes against Prostate Cancer

  • Ryu, Jei-Man;Seong, Seung-Kyoo;Bae, Eun-Jung;Song, Young-Jun;Jung, Yong-Ho;Kwak, Chul;Park, Mun-Soo;Lee, Sang-Eun;Shigematsu, Akiyo
    • Proceedings of the PSK Conference
    • /
    • 2003.04a
    • /
    • pp.156.2-157
    • /
    • 2003

  • 166Ho-chitosan complex (HC) is a new radiopharmaceutical approved in Korea for liver cancer. In these studies, therapeutic effect against prostate cancer and biodistribution of HC were evaluated in animal models using the technique of intraprostatic administration. For evaluation of the therapeutic effect, noble rats with AIT orthotopic or subcutaneous prostate cancer were used. (omitted)

  • PDF